Protagenic Therapeutics, Inc. (PTIX)
- Previous Close
0.5463 - Open
0.5511 - Bid --
- Ask --
- Day's Range
0.5300 - 0.5641 - 52 Week Range
0.4900 - 1.8700 - Volume
5,552 - Avg. Volume
233,148 - Market Cap (intraday)
2.458M - Beta (5Y Monthly) 0.28
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4500 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
www.protagenic.comRecent News: PTIX
View MorePerformance Overview: PTIX
Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PTIX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PTIX
View MoreValuation Measures
Market Cap
2.46M
Enterprise Value
-2.39M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.11
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-90.17%
Return on Equity (ttm)
-206.36%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-6.4M
Diluted EPS (ttm)
-1.4500
Balance Sheet and Cash Flow
Total Cash (mrq)
924.6k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.12M